Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Titel:
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Auteur:
Miles, D. Ciruelos, E. Schneeweiss, A. Puglisi, F. Peretz-Yablonski, T. Campone, M. Bondarenko, I. Nowecki, Z. Errihani, H. Paluch-Shimon, S. Wardley, A. Merot, J.-L. Trask, P. du Toit, Y. Pena-Murillo, C. Revelant, V. Klingbiel, D. Bachelot, T.